![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Daclatasvir Exposure Alone Does Not Explain HCV Relapse in HIV-HCV Coinfected Patients Receiving Daclatasvir Plus Sofosbuvir with Ritonavir-Boosted Darunavir in the ALLY-2 Study
|
|
|
Reported by Jules Levin
AASLD 2015 Nov 13-17 San Francisco, CA
Garimella T, Gandhi Y, Wang R, Ackerman P, Liu Z, Raybon J, Cirincione B, LaCreta F, Eley T
Bristol-Myers Squibb Research and Development, Princeton, NJ
![AASLD1.gif](../images/111815/111815-8/AASLD1.gif)
![AASLD2.gif](../images/111815/111815-8/AASLD2.gif)
![AASLD3.gif](../images/111815/111815-8/AASLD3.gif)
![AASLD4.gif](../images/111815/111815-8/AASLD4.gif)
![AASLD5.gif](../images/111815/111815-8/AASLD5.gif)
![AASLD6.gif](../images/111815/111815-8/AASLD6.gif)
![AASLD7.gif](../images/111815/111815-8/AASLD7.gif)
![AASLD8.gif](../images/111815/111815-8/AASLD8.gif)
![AASLD9.gif](../images/111815/111815-8/AASLD9.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|